Cervical myelography with iohexol.
An open study with iohexol (Omnipaque) in cervical myelography has been performed in 20 patients to evaluate the properties and neurotoxicity of this new water soluble contrast medium. The image quality was good (30%) or excellent (70%) in all cases. The frequency of headache was 25%. No EEG changes were severe and the total frequency was 20%. We conclude that this study supports other reports of iohexol having a low neurotoxicity and is well suited for intrathecal use.
D000328:Adult; D000368:Aged; D003287:Contrast Media; D004341:Drug Evaluation; D004569:Electroencephalography; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007405:Intervertebral Disc Displacement / Q000000981:diagnostic imaging; D007463:Iodobenzoates; D007472:Iohexol; D008297:Male; D008875:Middle Aged; D009192:Myelography / Q000379:methods; D009325:Nausea / Q000139:chemically induced; D013118:Spinal Cord Diseases / Q000000981:diagnostic imaging; D013130:Spinal Stenosis / Q000000981:diagnostic imaging; D014283:Triiodobenzoic Acids / Q000009:adverse effects
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007472:Iohexol